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Abstract 
Purpose: Tamoxifen is an anti-estrogenic drug that is widely used for endocrine-dependent breast cancer as adju-
vant hormonal therapy, and its use has been reported to be frequently associated with high levels of serum estradiol. 
Since the population of premenopausal women receiving tamoxifen therapy is growing in Japan, we retrospectively 
analyzed the incidence of ovarian hyperstimulation by tamoxifen therapy in Japanese women.
Methods: Eleven patients who received surgical therapy for endocrine-dependent breast cancer and showed high 
values of serum estradiol during post-operative tamoxifen therapy were recruited in this study and evaluated by 
examining the serum concentration of follicular stimulating hormone (FSH) and follicular development.
Results: The mean age, serum concentrations of estradiol and FSH, and follicular diameter were 41.3 years old, 
1015.8 pg/mL, 11.8 mIU/mL, and 3.47 cm, respectively. In 6 cases, multiple follicular development was observed, while 
the other cases showed single follicular development with a mean serum estradiol level of 848.6 pg/mL and follicular 
diameter of 4.46 cm. There was no significant difference in age or FSH concentration between the two groups. The 
mean periods from the start of the single administration of tamoxifen to the initial detection of a high estradiol con-
centration was 716.5 days.
Conclusions: These findings indicate that tamoxifen could stimulate the ovarian function even after 2-year treat-
ment. Since single and multiple follicular developments with large sizes were observed, dual mechanisms through 
the inhibition of both negative and positive feedback to the hypothalamic-pituitary-axis can be proposed to explain 
the adverse effects of tamoxifen on ovarian function.
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Background
In contrast to other industrial countries, the incidence of 
breast cancers has constantly increased since the 1990s 
in Japan along with the habitual changes of food intake 
from Japanese to Western styles (Katanoda et  al. 2015). 
Consequently, the Japanese population receiving hormo-
nal therapy for estrogen-dependent breast cancer during 
the premenopausal period has also been gradually grow-
ing, with a concomitant increase in the incidence rate of 
breast cancer (Uchida et al. 2015).
Tamoxifen (TAM), a nonsteroidal anti-estrogen drug, 
is widely used for the treatment of patients with all stages 
of estrogen-dependent breast cancer, and the long-term 
single use of tamoxifen has been applied to treat patients 
during the premenstrual period (Burstein et al. 2014). In 
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accordance with this trend, the Japanese Breast Cancer 
Society also recommended a single use of TAM more 
than for 5 years for premenstrual patients with estrogen-
dependent breast cancer (Mukai et al. 2015).
On the other hand, it was reported that treatment with 
TAM as a single agent for estrogen-dependent breast 
cancer during the premenopausal period is associated 
with a one- to three-fold increase of the serum levels of 
estradiol and progesterone (Jordan et  al. 1994). It was 
also proposed that TAM potentially stimulates the ovar-
ian function accompanied by formation of persistent 
follicular functional cysts in the premenopausal women 
(Shulman et al. 1994; Shushan et al. 1996; Mourits et al. 
1999; Cohen et al. 1999). Recently, Madeddu et al. (2014) 
reported two cases of multiple follicular development 
along with high estradiol concentrations of 1200 and 
698.8  pg/mL, respectively and pointed out the possible 
involvement of the direct effects of tamoxifen on ovarian 
function (Groom and Griffiths 1976).
The pathological conditions of polycystic ovarian syn-
drome in Japan, which is associated with a disorder of 
hormonal conversion from androgen to estrogen in the 
growing follicles, were reported to be markedly differ-
ent from those of Western countries (Mori et  al. 2009). 
Therefore, we should note the possibility that the ovar-
ian response of Japanese women against anti-estrogen 
drugs varies from that of women in Western countries. 
However, the side effects of TAM on the ovarian function 
have not yet been thoroughly analyzed in Japan. There-
fore, in this study, we retrospectively analyzed Japanese 
patients who showed high levels of serum estradiol dur-
ing TAM therapy for estrogen-dependent breast cancer 
during the premenopausal period.
Methods
From August 2013 to August 2014, 62 patients who 
received post-operative TAM therapy for endocrine-
dependent breast cancer (stage I–III) visited the out-
patient clinic of the Department of Breast Oncology in 
Kanazawa University Hospital. When the serum concen-
tration of estradiol was higher than 400  pg/mL, which 
exceeds the normal estradiol production by a single 
preovulatory follicle, these patients were immediately 
recommended to consult the Department of Gynecol-
ogy in Kanazawa University Hospital. At the gynecologi-
cal clinic, hormonal conditions were evaluated again by 
measuring serum concentrations of FSH and estradiol, 
while follicular development was further observed by 
ultrasonographic examination.
Among 62 candidates, 11 patients showed high values 
of serum estradiol during TAM therapy and visited the 
Department of Gynecology within 2 weeks following the 
previous blood sampling. These 11 cases were recruited 
into this study and hormonal and ultrasonographic data 
were retrospectively analyzed.
Estradiol and FSH were measured by electro-chemilu-
minescence immunoassay (ECLIA) kits (Roche Diagnos-
tics K.K., Tokyo, Japan). Data on serum concentrations of 
estradiol and FSH and follicular diameters are expressed 
as means  ±  standard deviations and the differences 
between the single and multiple follicular development 
groups, and the chemotherapy-treated and untreated 
groups, were analyzed by the unpaired t test. On the 
other hand, the differences in durations of single TAM 
treatment until the initial detection of a high concentra-
tion of estradiol were analyzed by the Mann–Whitney 
U-test.
This study was approved by the Medical Ethics Com-
mittee of Kanazawa University.
Results
The profiles of the 11 patients are summarized in Table 1. 
The mean age was 41.3 ± 7.34 years old. The serum con-
centrations of estradiol and FSH were 1015.8 ± 365.5 pg/
mL and 11.8 ± 8.36 mIU/mL, respectively. The mean fol-
licular diameter was 3.47 ± 1.91 cm. In 6 cases, multiple 
follicles (2–4 follicles) were observed and the mean serum 
concentration of estradiol and its value per follicle were 
1155.2  ±  414.8 and 460.7  ±  195.8  pg/mL, respectively. 
On the other hand, the other 5 cases showed single folli-
cular development and the mean serum concentration of 
estradiol and follicular diameter were 848.6 ± 234.2 pg/
mL and 4.46 ± 2.33 cm, respectively. There was no signif-
icant difference in the age or FSH concentration between 
the two groups.
The mean duration from the start of the single admin-
istration of TAM to the initial detection of a high con-
centration of estradiol was 716.5  ±  463.4  days. In the 
group treated with chemotherapy, the mean duration 
was 743.0  ±  597.8 (137–1825) days, while the mean in 
the group without chemotherapy was 684.8  ±  296.4 
(364–1054) days, showing no significant differences. 
Similarly, there were no differences in the estradiol 
concentration between the chemotherapy-treated 
group (956.7  ±  425.3  pg/mL) and non-treated group 
(1087.4 ± 310.1 pg/mL).
Discussion
In this study, adverse effects of TAM on the ovarian 
function during hormone therapy for breast cancers 
were observed in Japanese women of reproductive age. 
Although the precise incidence rate is unclear, consider-
ing the low frequency of post-operative follow-up, 2 or 
3 visits a year, the association of a high concentration of 
serum estradiol with TAM therapy may be a relatively 
common phenomenon in Japanese patients.
Page 3 of 5Yamazaki et al. SpringerPlus  (2015) 4:425 
The formation of a couple of ovarian follicular cysts 
was observed not only in three cases with regular men-
struation, but also in the other three cases that had been 
clinically diagnosed as chemotherapy-induced meno-
pause. This suggests that TAM can induce multiple follic-
ular development, which is usually observed in ovulation 
induction using an anti-estrogenic agent, clomiphene 
(Nasseri and Ledger 2001). Anti-estrogenic drugs are 
considered to inhibit the hypothalamic-pituitary-axis by 
negative feedback to stimulate the secretion of pituitary 
gonadotropins such as FSH and luteinizing hormone 
(LH) (Fig.  1). Since the pulsatile secretion of pituitary 
gonadotropins is important in the selection and/or pro-
motion of follicular development (Skorupskaite et  al. 
2014), more examinations including the rhythmic 
changes in pulsatile secretion by TAM are necessary to 
clarify the precise mechanisms.
Theoretically, the anti-estrogenic effects on the hypo-
thalamic-pituitary-axis also interfere with positive feed-
back, leading to inhibition of the LH surge (Fig. 2). Once 
the LH surge occurs, granulosa cells in the mature folli-
cles will undergo luteinization, in which the steroid hor-
mone production shifts from estradiol to progesterone 
(Devoto et al. 2002). Therefore, the formation of the sin-
gle functional follicular cyst that produced estradiol at 
more than 500 pg/mL in the serum, strongly suggests the 
absence of the LH surge.
Although the direct effects of TAM on steroid hor-
mone production of granulosa cells in the follicles were 
proposed to explain the high concentration of serum 
estradiol in the TAM-treated patients (Groom and Grif-
fiths 1976), our findings could not confirm the presence 
of this mechanism since the inhibitory effects of TAM on 
estrogen-induced negative and positive feedbacks to the 
hypothalamic-pituitary-axis could successfully explain 
the ovarian hyper-stimulated phenomenon observed in 
this study.
It should also be noted that four cases, with a mean of 
36.5 ± 8.35 years old, had been diagnosed with chemo-
therapy-induced menopause. However, a high value of 
serum estradiol was observed during the amenorrheic 
period that had continued from chemotherapy. Further-
more, in three of the four cases, these episodes were 
detected more than 1  year after the initiation of TAM 
Table 1 Clinical profiles of 11 cases with high concentration of serum estradiol during TAM treatment
NAC neoadjuvant chemotherapy, Ns numbers, dia. diameters, E2 estradiol, Tx treatment, Fl follicular, Chemo chemotherapy, Chemo-M chemotherapy-induced 
menopause
















1 54 I 1556 4.4 2 778 2 364 Regular
2 46 I 1028 9.3 2 514 4.7 872 Regular
3 29 IIa Done 1600 9.9 4 400 2.5 889 Chemo-M
4 43 I 1202 8 4 300 2.5 1054 Regular
5 46 IIb Done 464 24.9 2 232 1.5 427 Chemo-M
6 30 IIIa Done 1081 12 2 540 2.7 137 Chemo-M
7 45 I 900 6.9 1 900 8.1 724 Regular
8 44 I 751 6 1 751 2.2 410 Irregular
9 36 IIa Done 898 7.7 1 898 4.3 791 Irregular
10 40 IIa Done 527 31.0 1 527 2.7 1825 Irregular
11 41 IIIc Done 1167 9.5 1 1,167 5 389 Chemo-M
Fig. 1 Inhibitory action of TAM on negative feedback to the 
hypothalamic-pituitary-axis by estrogen during the follicular phase. 
TAM can inhibit negative feedback to the hypothalamic-pituitary-axis 
by estrogen, leading to the increases of FSH and LH secretion by the 
pituitary gland and then inducing multiple follicular development
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treatment. From these findings, we suggest an important 
consideration that anovulatory hyperestrogenic condi-
tions may be induced by TAM treatment even during the 
amenorrheic period in patients diagnosed with chemo-
therapy-induced menopause.
In addition, there was no significant difference in the 
duration from the start of single administration of TAM 
to the initial detection of a high concentration of estradiol 
between both chemotherapy-treated and non-treated 
groups. Importantly, although previous reports suggested 
that the development of an ovarian cyst is extremely rare 
after 2  years of TAM treatment (Madeddu et  al. 2014), 
the average duration in both groups in this study was 
around 700  days, indicating that ovarian hyperstimula-
tion can occur after 2-year treatment with TAM in Japa-
nese women. Therefore, the risk of TAM-induced ovarian 
hyperstimulation should be considered throughout TAM 
treatment in Japan.
In conclusion, our findings indicate that anti-estrogenic 
hormonal treatment by TAM could stimulate the ovar-
ian function even after single treatment for more than 
2 years. Since single and multiple follicular developments 
were equally observed and follicular sizes were relatively 
large, we propose dual mechanisms of adverse effects of 
TAM on the ovarian function, that is, mediated through 
the inhibition of both negative and positive feedbacks to 
the hypothalamic-pituitary-axis.
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